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ABSTRACT
The hexanucleotide G4C2 repeat expansion in the first intron of the
C9ORF72 gene accounts for the majority of frontotemporal dementia
(FTD) and amyotrophic lateral sclerosis (ALS) cases. Numerous
studies have indicated the toxicity of dipeptide repeats (DPRs), which
are produced via repeat-associated non-AUG (RAN) translation from
the repeat expansion, and accumulate in the brain of C9FTD/ALS
patients. Mouse models expressing the human C9ORF72 repeat and/
or DPRs show variable pathological, functional and behavioral
characteristics of FTD and ALS. Here, we report a new Tet-on
inducible mouse model that expresses 36× pure G4C2 repeats with
100-bp upstream and downstream human flanking regions. Brain-
specific expression causes the formation of sporadic sense DPRs
aggregates upon 6 months of dox induction, but no apparent
neurodegeneration. Expression in the rest of the body evokes
abundant sense DPRs in multiple organs, leading to weight loss,
neuromuscular junction disruption, myopathy and a locomotor
phenotype within the time frame of 4 weeks. We did not observe any
RNA foci or pTDP-43 pathology. Accumulation of DPRs and the
myopathy phenotype could be prevented when 36× G4C2 repeat
expression was stopped after 1 week. After 2 weeks of expression, the
phenotype could not be reversed, even though DPR levels were
reduced. In conclusion, expression of 36× pure G4C2 repeats including
100-bp human flanking regions is sufficient for RAN translation of
sense DPRs, and evokes a functional locomotor phenotype. Our
inducible mouse model suggests that early diagnosis and treatment
are important for C9FTD/ALS patients.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
Frontotemporal dementia (FTD) is a neurological disease
characterized by neuronal loss in the frontal and temporal lobes,
leading to behavioral and personality changes, and language deficits
(Hernandez et al., 2018;Woollacott andRohrer, 2016). The prevalence
of FTD is ∼15-20 cases per 100,000 people, and the age of onset is
usually between 45 to 65 years (Woollacott and Rohrer, 2016). FTD is
part of a disease spectrum that also comprises amyotrophic lateral
sclerosis (ALS) (Couratier et al., 2017; Strong et al., 2017). ALS is a
rapid progressive motor neuron disorder that affects the upper motor
neurons in themotor cortex and the lowermotor neurons in the anterior
horn of the spinal cord (Grad et al., 2017; Oskarsson et al., 2018). ALS
patients develop muscle weakness, spasticity, atrophy and eventually
paralysis (Grad et al., 2017; Oskarsson et al., 2018). The prevalence of
ALS is ∼5 in 100,000 people, and the age of onset is between 50 and
60 years of age (Grad et al., 2017; Oskarsson et al., 2018). The
hexanucleotide G4C2 repeat expansion in theC9ORF72 gene accounts
for almost 90% of the families presenting with both FTD and ALS
symptoms (referred to as C9FTD/ALS; DeJesus-Hernandez et al.,
2011; Renton et al., 2011). Patients can be mosaic for repeat size and
often have longer repeats in brain tissue than in DNA isolated from
blood samples (Fournier et al., 2019; Nordin et al., 2015; van
Blitterswijk et al., 2013). So far, repeat sizes of 24-4400 have been
reported (Iacoangeli et al., 2019; Van Mossevelde et al., 2017).
Associations between repeat size and clinical diagnosis have not
resulted in a clear picture (Fournier et al., 2019; Gijselinck et al., 2016;
van Blitterswijk et al., 2013). Thus, the exact repeat size that triggers
disease onset is not known.
Three mechanisms for the C9ORF72 repeat expansion have been
proposed to cause C9FTD/ALS (Balendra and Isaacs, 2018). First,
hypermethylation of the repeat and surrounding CpG islands can lead
to reduced levels of the normal C9ORF72 protein (Belzil et al., 2013;
Waite et al., 2014). C9orf72 knockout mice have shown its essential
function in immunity, but do not present with FTD or ALS symptoms
(Balendra and Isaacs, 2018). However, haploinsufficiency can still
modify the effects of gain-of-function mechanisms via the normal
cellular function of the C9ORF72 protein in autophagy and lysosomal
biogenesis (Sellier et al., 2016; Shi et al., 2018). Second, repeat-
containing RNA from both sense and antisense directions can form
secondary structures (Kovanda et al., 2015; Su et al., 2014) and RNA
foci (Gendron et al., 2013; Mizielinska et al., 2013). Repeat-
containing RNA or RNA foci can sequester RNA-binding proteins
and prevent their normal functioning in the cell (Haeusler et al., 2016).
Third, the G4C2 repeat can also be translated into dipeptide repeats
(DPRs) via repeat-associated non-ATG (RAN) translation (Ash et al.,
2013; Gendron et al., 2013;Mori et al., 2013). RAN translation occurs
in all reading frames of sense and antisense transcripts and results in
the formation of poly-glycine-alanine (GA), poly-glycine-proline
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(GP), poly-glycine-arginine (GR), poly-proline-alanine (PA) and
poly-proline-arginine (PR). DPRs have been found throughout the
brains of C9FTD/ALS patients (Mackenzie et al., 2015) and poly-GR
has particularly been associated with neurodegeneration (Gittings
et al., 2020; Saberi et al., 2018; Sakae et al., 2018). Multiple cell and
animal models have indicated the detrimental effect of the expression
of both arginine-containing DPRs, poly-GR and poly-PR, and the
slightly less toxic poly-GA (Balendra and Isaacs, 2018; Boeynaems
et al., 2016; Jovicic et al., 2015; Kanekura et al., 2016; Kwon et al.,
2014; Mizielinska et al., 2014; Swaminathan et al., 2018; Tao et al.,
2015; Wen et al., 2014; Yamakawa et al., 2015; Yang et al., 2015). So
far, 11 loss-of-function and ten gain-of-function C9ORF72 mouse
models have been published (reviewed by Balendra and Isaacs, 2018;
Batra and Lee, 2017), as well as five DPR-only mouse models
investigating the role of poly-GA (Schludi et al., 2017; Zhang et al.,
2016), poly-GR (Zhang et al., 2018) and poly-PR (Hao et al., 2019;
Zhang et al., 2019). All mouse models support a gain-of-function
hypothesis in C9FTD/ALS, although not all BAC mice show
neurodegeneration or a motor phenotype associated with ALS
(reviewed by Balendra and Isaacs, 2018; Batra and Lee, 2017). The
effect of DPRs has been studied extensively (reviewed by Balendra
and Isaacs, 2018), but possible reversibility and the exact number of
repeats needed for RAN translation in vivo have yet to be determined
(Cleary et al., 2018; Green et al., 2016).
Here, we describe a new mouse model that expresses human
C9ORF72 36× pure G4C2 repeats with 100-bp upstream and
downstream human flanking regions under the expression of an
inducible Tet-on promoter. This system allows for temporal and
spatial expression of the repeat expansion. Expression of 36× pure
G4C2 repeats was sufficient to produce sense DPRs and a locomotor
phenotype upon 4 weeks of induction of expression. In order to
study possible reversibility, expression was stopped after 1 or
2 weeks, followed by a washout period of 2-3 weeks to prevent
further build-up and subsequent reduction of the amount of DPRs.
RESULTS
Generation and expression pattern of the human 36× G4C2
repeat mouse model
We generated our mouse model from DNA isolated from the blood of
a C9FTD patient and amplified the repeat in three consecutive PCR
rounds using primers that flanked the C9ORF72 repeat expansion (for
primer sequences see Materials and Methods). The PCR product was
cloned into a TOPO vector and subsequently into a Tet-on vector with
a GFP reporter gene (Hukema et al., 2014) (Fig. 1A). Sequencing of
this construct revealed a repeat size of 36× pure G4C2 repeats with
118-bp upstream and 115-bp downstream human flanking regions
(Fig. S1). The transgene (containing the TRE promoter, 36× G4C2
repeats and the GFP gene) was injected into pronuclei of C57BL/6J
mice. Founder mice were screened for the presence and size of the
transgene and transmission to their offspring (n=3 lines containing the
repeat, 1 linewith expression). Genotyping for transgene presencewas
performed with primers located upstream of the repeat. Repeat size
estimation was established using the Asuragen C9ORF72 repeat kit
that is also used in routine human diagnostics. Repeat size remained
Fig. 1. Generation and expression of the 36×G4C2 repeatmousemodel. (A) Schematic of the Tet-on system.Mice either have aCamk2-alpha-rtTA or hnRNP-
rtTA transgene that expresses rtTA in a brain-specific manner or in the whole body. Upon binding of dox, rtTA can bind the TRE response element and start
transcription of the C9ORF72 G4C2 repeat expansion and GFP gene, which has its own start site. During the whole study, ST littermates were used as a
control and received the same dox treatment. (B) DNA isolated from different tissues from the same mouse (17129-5 ladder mouse on dox for 4 weeks), and
analyzed with an Asuragen C9ORF72 PCR kit, showed a repeat length of 36 in all tissues. This was repeated in at least three independent mice. OL, out
of limit. (C) Upper panel: GFP expression was detected in striatum and hippocampus cornu ammonis and hippocampus dentate gyrus in DT Camk2-alpha-rtTA/
TRE-36G4C2-GFP mice after dox administration. Lower panel: GFP expression in EDL muscle, kidney and liver of DT hnRNP-rtTA/TRE-36×G4C2-GFP mice.
GFP staining was performed on all mice in this study. ST, 4 weeks dox, n=15; DT, 4 weeks dox, n=16. Scale bars: 20 µm.
2


















stable between generations and between multiple organs of the same
mouse (Fig. 1B). Transgenic micewere born atMendelian frequencies
and showed normal viability.
Heterozygous transgenic mice containing the TRE-36×G4C2-GFP
construct were bredwith two different heterozygous rtTA driver lines.
We chose the CamK2α (Ca2+/calmodulin-dependent protein kinase II
linked reverse tetracycline-controlled transactivator) rtTA driver
because of its validated expression in the hippocampus and cortex,
brain areas that exhibit pathology in C9FTD/ALS patients (Odeh
et al., 2011). To study expression in the rest of the body, we used an
hnRNP (heterogeneous nuclear ribonucleoprotein 2B1) rtTA driver.
The resulting litters consisted of four different genotypes referred to
in the rest of the paper as double transgenic (containing both the TRE-
36×G4C2-GFP construct and one of the rtTA constructs) or single
transgenic littermates (containing only the TRE or only an rtTA-
driver construct). Wild-type littermates were not used in this study.
Mice were administered doxycycline (dox) in their drinking water at
6 weeks of age to turn on transgene expression, which revealed
specific expression of GFP in the double transgenic (DT) mice only
and no transgene expression in single transgenic (ST) mice (Fig. S2).
Using the hnRNP-rtTA driver, we observed expression in almost all
tissues, including extensor digitorum longus (EDL) muscle, liver,
kidney (Fig. 1C) heart and lung (Fig. S2), but not in brain and spinal
cord after a maximum of 4 weeks of dox treatment (Fig. S2). Using
the Camk2-alpha-rtTA driver, we observed GFP expression only in
striatum and hippocampus dentate gyrus and cornu ammonis, as
expected (Fig. 1C). GFP expression was detectable after 1 week of
dox administration and remained detectable over 6 months (data not
shown).
Human 36× G4C2 repeat mice show DPR expression but no
RNA foci
To further characterize the expression of the transgene in our mouse
model, we performed fluorescence in situ hybridization (FISH) to
test for the presence of sense and antisense RNA foci.
Unfortunately, we were unable to detect RNA foci in multiple
organs at 1-24 weeks of age in any of the driver lines (Fig. S3),
despite the fact that our protocol was optimized to detect RNA foci
in post-mortem human C9FTD/ALS frontal cortex paraffin tissue
used as a positive control (Fig. S3). Sense-transcribed DPRs (poly-
GA, -GP and -GR) were present in all GFP+ tissues of DT hnRNP-
rtTA mice (Fig. 2). We did not observe antisense DPRs in mice
(Fig. 2C-F), although we could detect them in C9FTD/ALS patient
frontal cortex sections that were used as a positive control
(Fig. 2A,B). To validate that no antisense transcripts were
produced in our mouse model, we performed RT-PCR (Fig. S4).
Again, antisense transcripts were only observed in RNA isolated
from frozen frontal cortex of a human C9FTD patient (Fig. S4).
Interestingly, senseDPRs differed in subcellular localization. Poly-
GA was visible as diffuse nuclear and cytoplasmic labeling in DT
hnRNP-rtTA mice, whereas poly-GP and -GR were only observed in
the nucleus (Fig. 2C,D; Fig. S5). In the DT Camk2-alpha-rtTA mice,
we could detect some small perinuclear aggregates in the striatum and
hippocampus after 24 weeks of dox administration (Fig. 2E,F).
However, the numbers of aggregates were very rare (about one
aggregate per sagittal brain section). Longer follow-up of these mice
is not possible, as administration of dox for more than 6 months often
leads to intestinal problems and an unacceptable level of discomfort
for the mice. Both Camk2- and hnRNP-driven 36×G4C2 repeat mice
showed no abundant pathological hallmarks of C9FTD/ALS,
including p62 and phosphorylated TAR DNA-binding protein
(pTDP-43) aggregates in brain and muscle (Fig. S6). Additionally,
we did not observe any signs of neurodegeneration (cleaved caspase-
3 staining, Fig. S6), astrogliosis or microgliosis (Fig. S7). As DPR
inclusions were very rare in Camk2-alpha-rtTA mice and expression
of DPRs was evident in the hnRNP-rtTA mice, we chose to focus on
the DT hnRNP-rtTAmice for further assessment of the toxic effect of
DPR expression in multiple organs in vivo.
The 36× G4C2 repeat mice develop a locomotor phenotype,
rapid muscular dystrophy and neuromuscular junction
abnormalities
Expression of 36× G4C2 repeats using the hnRNP-rtTA driver led to
profound toxicity. We started with dox treatment in 6-week-old mice
to avoid DPRs affecting normal development, which would
complicate behavioral and functional read-out. A large proportion
(45%) of DT mice quickly declined in body weight in the first
2-3 weeks after dox administration and had to be sacrificed (Fig. 3A).
Mice that quickly lost weight after 2.5 weeks showed general
sickness symptoms (weight loss, bad condition of the fur, reduced
activity and shivering) and an enlarged bladder. The majority of mice
survived longer and did not lose weight but developed a locomotor
phenotype on the Erasmus ladder (Fig. 3B; Fig. S8). This is a
locomotor test based upon a horizontal ladder with alternating higher
and lower rungs. Healthy C57Bl6/J mice prefer to walk on the higher
rungs and avoid touching the lower rungs (Vinueza Veloz et al.,
2015). DT mice began to touch the lower rungs more often after
2 weeks of dox treatment, although their performance was initially
comparable to that of their ST littermates (Fig. 3B; Fig. S8; two-way
ANOVA analysis: P=0.0001 for genotype and P<0.0001 for the
interaction between genotype and time). DT mice sacrificed after
4 weeks of dox treatment displayed a white appearance of leg and
back muscles macroscopically (Fig. 3C). At the histological level, a
massive distortion of muscle fibers could be observed (Fig. 3D).
Histological analysis of other tissues revealed enlarged renal tubules
in the kidney and hemorrhages in the bladder of mice that quickly lost
weight at 2.5 weeks (Fig. 3D). Analyses of the neuromuscular
junctions (NMJs) by whole-mount immunostaining of the EDL
muscle showed distortion of the muscular boutons and projecting
motor neuron axons after 4 weeks of dox treatment (Fig. 3E). The
number of motor neurons assessed by choline acetyltransferase
(ChAT) staining of the spinal cord was not different betweenDTmice
and ST control littermates (Fig. 3F). Together, these data indicate that
expression of 36 pure G4C2 repeats in the body (but not expression in
the brain) in our mouse model causes multisystem dysfunction,
including urinary system problems and muscular dystrophy over the
time course of 1 month.
Early withdrawal of 36× G4C2 repeat expression can prevent
but not reverse the muscular dystrophy phenotype
In order to investigate whether the phenotype could be reversed, we
administered dox to 6-week-old DT and ST mice for 1 or 2 weeks
and then changed them back to normal drinking water for 3 and
2 weeks, respectively (washout scheme shown in Fig. 4A). Mice
that only received 1 week of dox followed by 3 weeks of washout
showed high survival rates and normal muscle and NMJ integrity
(Fig. 4). Approximately half of the DT mice that received 2 weeks
of dox followed by 2 weeks of washout showed a rapid reduction in
body weight after 2-3 weeks and did not survive to the end of the
experiment (Fig. 4B). This washout group was indistinguishable
from the 4 weeks dox DT group, with regards to survival, muscle
and NMJ integrity. Haematoxylin and eosin (H&E) staining showed
that parts of the EDL displayed abnormal organization (Fig. 4C),
and the NMJ showed disrupted boutons and axonal projections
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(Fig. 4D). Immunostaining for GFP, poly-GA and -GP inmuscles of
both washout groups showed a clear reduction in their levels but
poly-GA and -GP were still detectable in nuclei of the 2 weeks on/
2 weeks off group (Fig. 5). Only poly-GR could not be detected
anymore (Fig. 5). In the kidney, GFP and all sense DPRs were
cleared efficiently after dox withdrawal (Fig. S9). This indicates that
DPR clearance is different for each organ or cell type. To study
build-up and reduction of DPRs in a more quantitative way, we
developed an ELISA for poly-GR, the DPR that shows the highest
reported cellular toxicity. Poly-GR levels in EDL muscle increased
significantly between the first and second week of dox
administration, after which they stayed high (Fig. 6). In contrast,
poly-GR levels in mice from the reversibility groups were reduced
to similar levels as ST control mice (one-way ANOVA test:
P=0.0001 with Bonferroni post test; Fig. 6). Together, our data
show that early withdrawal of 36× pure G4C2 repeat expression can
prevent the accumulation of DPRs and the concurrent phenotype.
Expression of 36× pure G4C2 repeat expression for 2 weeks and
subsequent withdrawal for 2 weeks is not sufficient to completely
clear DPRs and reverse muscular dystrophy in vivo.
DISCUSSION
In this study, we demonstrate that expression of 36× pure G4C2
repeats in vivo is sufficient to cause NMJ abnormalities and
Fig. 2. Expression of 36× G4C2 human repeats is sufficient to evoke sense DPR formation in vivo. (A,B) Human prefrontal cortex of C9FTD patients (A) or
non-demented controls (B) were used as positive and negative controls for the detection of DPR pathology. Arrows indicate perinuclear aggregates of DPRs.
(C) In TRE-36×G4C2-GFP/hnRNP-rtTA DT mice, poly-GA showed both diffuse cytoplasmic and nuclear localization, whereas diffuse poly-GP and poly-GR
were observed in the nucleus of the EDL muscle. (D,F) ST littermates received the same dox treatment and contained only one transgene, either TRE only
or rtTA only, and were all negative for DPRs. (E) TRE-36×G4C2-GFP/Camk2-alpha-rtTA DTmice showed some sparse perinuclear aggregates of sense DPRs in
the hippocampus dentate gyrus (indicated by arrows). DPR staining was performed on all mice in this study. ST, 4 weeks dox, n=15; DT, 4 weeks dox, n=16.
Scale bars: 20 µm.
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muscular dystrophy, leading to a specific locomotor phenotype
within 4 weeks of transgene expression. Expression for 4 weeks did
not evoke DPR expression in the brain, probably because 4 weeks
are not long enough for build-up of DPRs and for dox to pass the
blood-brain barrier (Michel et al., 1984). Expression of 36× pure
G4C2 repeats for 24 weeks in the murine brain, using a Camk2-
alpha-rtTA driver, was also not sufficient to result in pathology or
neurodegeneration, making this mouse model inadequate for
studying brain-specific DPR toxicity. We speculate that
expression levels of the 36× G4C2 repeat RNA and DPRs in our
Fig. 3. Expression of 36× G4C2 human repeats in vivo causes a locomotor phenotype and muscular dystrophy within 4 weeks. (A) TRE-36×G4C2-GFP/
hnRNP-rtTA DT mice that receive dox showed reduced survival after 1-3 weeks (n=18) compared to ST littermates [containing only one transgene (either TRE
only or rtTA only)] who received the same dox treatment (n=11). (B) Mice that survive developed a locomotor phenotype on the Erasmus ladder after
7 sessions (3 sessions/week). N=12 mice per group. Note that from session 7 onwards, some mice had to be excluded due to severe pathology or incapability to
cope with the behavioral assay. Session 12 includes data from N=10 ST control and N=8 DT mice. All mice received the same dox treatment. *P=0.0001 for
genotype and P<0.0001 for the interaction between genotype and time (two-way ANOVA). Data are mean±s.e.m. (C) When sacrificed, DT mice exhibited back
and upper legmuscles with awhite appearance (indicated by arrows). (D) H&E staining of the EDLmuscle, kidney and bladder of DTmice. (E) NMJ staining of the
EDL muscle showed dissolving boutons (red, α-bungarotoxin) and disorganized axonal projections (green, neurofilament antibody). (F) The number of
ChAT+ motor neurons in the spinal cord did not differ between DT and ST control littermates. All stainings were performed on all mice in this study. ST, 4 weeks
dox, n=15; DT, 4 weeks dox, n=16. Scale bars: 50 µm (D, EDL and kidney images); 200 µm (D, bladder images); 50 µm (E); 20 µm (F).
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Camk2-alpha-rtTA driven model are not high enough to induce
neuropathology. Alternatively, the repeat length might not be long
enough to evoke neurodegeneration. Other gain-of-function mouse
models did show sense DPR pathology and a cognitive phenotype
upon (over)expression of longer repeats (Chew et al., 2015;
Herranz-Martin et al., 2017; Jiang et al., 2016; Liu et al., 2016).
Mice expressing 500 repeats show a more severe phenotype
compared with 29/36 repeat mice (Liu et al., 2016).
Upon expression of 36× pure G4C2 repeats in the body, our mouse
model shows rapid muscular dystrophy and a locomotor phenotype.
The phenotype could be caused by NMJ abnormalities or skeletal
muscle dysfunction. Interestingly, DPR pathology has recently been
found in skeletal muscle of C9ALS patients (Cykowski et al., 2019).
DPR pathology has not been reported in human in tissues such as the
kidney and bladder, even though C9ORF72 is expressed in these
organs and C9KO mice show immune-mediated kidney damage
(Atanasio et al., 2016; DeJesus-Hernandez et al., 2011). The
pathology in our mouse model could be evoked by the relative
rapid and strong repeat expression compared to the lower expression
levels observed in C9FTD/ALS patients, but it would be interesting to
investigate how widespread DPR pathology is. Many C9ORF72
mouse models lack locomotor symptoms due to unknown factors
(Jiang et al., 2016; O’Rourke et al., 2015; Peters et al., 2015), and
NMJ abnormalities have only been described in one BAC mouse
model and one AAV-102x interrupted G4C2 mouse model (Herranz-
Martin et al., 2017; Liu et al., 2016). Our mouse model shows
Fig. 4. Early dox withdrawal can prevent but not reverse the muscular dystrophy and NMJ phenotype of TRE-36×G4C2-GFP/hnRNP-rtTA DT mice.
(A) Schematic of different washout groups. (B) Survival curve for the washout experiment. Mice that received 1 week dox followed by 3 weeks washout
(1 week on/ 3 weeks off, n=7) showed high survival. Twoweeks dox followed by 2 weeks washout (2 weeks on/ 2 weeks off, n=15) showed the same reduction in
survival as 4 weeks continuous dox administration (4 weeks on, n=13). ST littermates [containing only one transgene (either TRE only or rtTA only)] were
distributed over the groups and received the same dox treatment (n=21). (C) H&E staining of the EDLmuscle remained normal in the 1 week on/ 3 weeks off group
but showed distortion in TRE-36×G4C2-GFP/hnRNP-rtTA DT mice that received 2 weeks dox followed by 2 weeks of normal drinking water. (D) NMJ of the
EDL muscle showed collapsed boutons (red, α-bungarotoxin) and axonal projections (green, neurofilament antibody) in DT groups that received 2 or more
weeks of dox. All stainings were performed on all mice in this study. Numbers per group were: ST, 1 week dox, n=7; DT, 1 week dox, n=8; ST, 1 week on/3 weeks
off, n=4; DT, 1 week on/3 weeks off, n=7; ST, 2 weeks dox, n=6; DT, 2 weeks dox, n=8; ST, 2 weeks on/2 weeks off, n=6; DT, 2 weeks on/2 weeks off,
n=5; ST, 4 weeks dox, n=15; DT, 4 weeks dox, n=16. Scale bars: 50 µm.
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similarities to the BAC 29/36 repeat mouse model reported by Liu
et al. (2016), as both models show DPR pathology but no RNA foci.
However, the phenotype in our mouse model develops faster (within
4 weeks after dox administration) than reported by Liu et al. (2016)
(first symptoms started after 16 weeks of age). Differences in disease
onset might be due to differences in expression levels. For example,
lack of a phenotype was observed in a 37 repeat mouse with low
expression levels (Liu et al., 2016), whereas our 36 repeat and the
BAC 29/36 repeat mousewith higher expression levels clearly show a
phenotype.
So far, the minimum repeat size to evoke RNA foci and DPR
formation in vivo has remained unknown. A BAC mouse model of
Fig. 5. GFP and sense DPRs are
reduced after dox withdrawal.
(A) GFP staining of EDL muscle of
TRE-36×G4C2-GFP/hnRNP-rtTA DT
mice showed a reduction in the
intensity of staining when mice
received 1 or 2 weeks of dox water,
followed by 2-3 weeks of normal
drinking water compared to DT
littermates that received 4 weeks of
dox. (B) Poly-GA staining of EDL
muscle showed clearance of
cytoplasmic poly-GA in all washout
groups but retention of nuclear poly-GA
after 2 weeks of dox withdrawal. (C,D)
Poly-GP staining is reduced in the
nucleus of EDL muscle (C) and Poly-
GR staining is cleared from nuclei of
EDL muscles after dox withdrawal (D).
ST littermates, consisting of either TRE
only or rtTA only, received the same
dox treatment and were all negative for
GFP and DPRs. All stainings were
performed on all mice in this study.
Numbers per group were: ST, 1 week
dox, n=7; DT, 1 week dox, n=8; ST,
1 week on/3 weeks off, n=4; DT,
1 week on/3 weeks off, n=7; ST,
2 weeks dox, n=6, DT, 2 weeks dox,
n=8; ST, 2 weeks on/2 weeks off, n=6;
DT, 2 weeks on/2 weeks off, n=5; ST,
4 weeks dox, n=15; DT, 4 weeks dox,
n=16. Scale bars: 20 µm.
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110 repeats did not contain any RNA foci (Jiang et al., 2016),
whereas BAC mice with longer repeat sizes did present with RNA
foci (Jiang et al., 2016; Liu et al., 2016; O’Rourke et al., 2015; Peters
et al., 2015). On the other hand, AAV-mediated overexpression of 10
or 66 repeats did evoke RNA foci (Chew et al., 2015; Herranz-Martin
et al., 2017), indicating that formation of RNA foci could also depend
on expression levels. Even though we did not detect any RNA foci in
our 36× repeat mouse model, we cannot exclude an effect of repeat
RNA on the observed phenotype. Repeat-containing RNAmolecules
might still be able to sequester molecules or proteins and affect their
normal function of cellular processes.
Sense DPRs were detected as diffuse cytoplasmic or nuclear
staining and did not form aggregates in our hnRNP-driven mouse
model. Recent publications on poly-GR and -PR mouse models
suggest that soluble poly-GR and -PR are sufficient to cause
neurodegeneration and behavioral deficits (Zhang et al., 2018, 2019).
For poly-GA, aggregation seems necessary for its toxicity (Zhang
et al., 2016). Thus, DPRs might differ in their abilities to aggregate,
which can change their molecular targets and their effects on several
cellular compartments and functions. Interestingly, poly-GA can
spread throughout the brain and influence the aggregation of poly-GR
and -PR (Darling et al., 2019; Morón-Oset et al., 2019; Yang et al.,
2015), and this has been confirmed in AAV-66 and AAV-149x mice,
in which poly-GA and -GR co-aggregate in cells with poly-GA
aggregates, but poly-GR remains diffuse in cells devoid of poly-GA
(Chew et al., 2019; Zhang et al., 2018). Poly-GA expression can even
partially suppress poly-GR-induced cell loss at the wing in a
Drosophila model (Yang et al., 2015). Co-overexpression of poly-
GA also abolished cellular toxicity of low concentrations of poly-PR
in NSC34 cells (Darling et al., 2019). Other interactions between
DPRs are still unknown and need further investigation. We did not
detect antisense DPRs in our mouse model, perhaps because
antisense C4G2 RNA is not transcribed or antisense DPR levels
might be too low to detect.
Another point of interest is the lack of apparent pTDP-43 pathology
in multiple C9ORF72mouse models. TDP-43 pathology is thought to
be a late event in the pathogenesis of C9FTD/ALS (Balendra and
Isaacs, 2018). Several mouse models already show behavioral
phenotypes and some mild neurodegeneration before the onset of
pTDP-43 neuropathology (Herranz-Martin et al., 2017; Jiang et al.,
2016; Schludi et al., 2017; Zhang et al., 2018, 2016). Changes in
pTDP-43 solubility or cellular localization could already arise and
contribute to cellular distress without the formation of cytoplasmic
aggregates per se (Lee et al., 2019). Indeed, several reports of C9FTD/
ALS cases showed affected individuals with DPR pathology but mild
or absent TDP-43 pathology (Baborie et al., 2015; Gijselinck et al.,
2012;Mori et al., 2013; Proudfoot et al., 2014; Vatsavayai et al., 2016).
Together, our hnRNP-driven mouse model shows that expression of
diffuse labeled sense DPRs is sufficient to cause cellular toxicity
without the need for RNA foci and pTDP-43 pathology.
The rapid translation of current knowledge into therapeutic
intervention studies requires robust in vivo drug discovery screens
(Jiang and Ravits, 2019). So far, antisense oligonucleotide (AON)
therapy has been tested in a BAC mouse model for C9ORF72, and
successfully reduced the amount of RNA foci and DPRs (Jiang et al.,
2016). However, it remains unknown whether this AON can also
reduce motor symptoms associated with the C9ORF72 repeat. New
therapies are under development, including small molecules targeting
RAN translation (Green et al., 2019; Hu et al., 2017; Kramer et al.,
2016; Simone et al., 2018; Su et al., 2014; Zamiri et al., 2014; Zhang
et al., 2015) and antibody therapy against poly-GA (Nguyen et al.,
2020; Zhou et al., 2019). These therapies can be easily tested in our
mousemodel, as it develops a quick and robust phenotype. Ourmouse
model can be used as proof of principle for whole-body toxicity of
DPRs. We demonstrated that 1 week of expression followed by
3 weeks of washout (expression turned off) prevented the
accumulation of DPRs and the associated cellular toxicity.
However, 2 weeks of expression followed by 2 weeks of washout is
not sufficient to prevent mice from developing muscular dystrophy.
This indicates that transgene RNA or DPRs that were already
produced during the first 2 weeks of dox administration continue to
exercise their toxic effects. A recent publication estimated the half-
lives of most DPRs to be >200 h (Westergard et al., 2019). The half-
life was longer for poly-GA puncta than for diffuse poly-GA, and
increased for poly-GR when localized in the nucleus (Westergard
et al., 2019). Interestingly, poly-GP remains detectable after 1 week
Fig. 6. Expression of 36×G4C2 human repeats in vivo
generates high levels of poly-GR, which are reduced
to ST level after dox withdrawal. ELISA assessing
poly-GR levels from mouse EDL muscle. Poly-GR was
detectable in TRE-36×G4C2-GFP/hnRNP-rtTA DT mice
that received 2-4 weeks of dox. DT mice that received
1-2 weeks dox followed by 2-3 weeks washout have
reduced amounts of poly-GR, similar to ST levels.
A one-way ANOVA (***P=0.0001) Bonferroni post test
shows that the DT 2 weeks dox and DT 4 weeks dox
groups were significantly different from all the other
groups, but not from each other. All other ST and DT
washout groups were not significantly different from
each other. ST littermates [consisting of only one
transgene (either TRE only or rtTA only)] received a
similar dox treatment asDTanimals. Numbers per group
were: ST, 1 week dox, n=7; DT, 1 week dox,
n=8; ST, 1 week on/3 weeks off, n=4; DT, 1 week on/
3 weeks off, n=7; ST, 2 weeks dox, n=6; DT, 2 weeks
dox, n=8; ST, 2 weeks on/2 weeks off, n=6; DT,
2 weeks on/2 weeks off, n=5; ST, 4 weeks dox, n=15;
DT, 4 weeks dox, n=16. Data are mean±s.e.m.
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on/3 weeks off dox, indicating that poly-GP is not turning over as
quickly as the other DPRs. Still, the animals of this reversibility group
are improving, suggesting a bigger impact on the toxicity of poly-GA
and poly-GR, as shown previously (Balendra and Isaacs, 2018;
Mizielinska et al., 2014). In general, earlier intervention might be able
to halt or reverse symptoms, but the preferred time window for
treatment is probably before the onset of symptoms.
Together, we provide evidence that the expression of human 36×
pure G4C2 repeats is sufficient to evoke RAN translation and a
locomotor phenotype in vivo. High expression of sense DPRs driven by
hnRNP-rtTA caused rapid progression of muscular dystrophy andNMJ
disruption. This mouse model allows for fast in vivo screening of new
drugs and compounds that act on the systemic toxicity of sense DPRs.
MATERIALS AND METHODS
Cloning
DNA obtained from C9FTD patient 09D-5781 was assessed for the
C9ORF72 repeat expansion with an Asuragen kit used according to
manufacturer’s protocol, and contained at least 54 repeats. DNA was
amplified in three consecutive rounds of PCR with primers flanking the
C9ORF72 repeat expansion (forward primer, 5′-CCACGGAGGGATGTT-
CTTTA-3′ and reverse primer, 5′-GAAACCAGACCCAAACACAGA-3′)
and a PCR mix containing 50% betaine. The PCR program started with
10 min at 98°C, followed by 35 cycles of 35 s at 98°C, 35 s at 58°C and 3 min
at 72°C and finished with 10 min at 72°C. The PCR product was cloned into
TOPO vector PCR2.1, and restriction analysis with BsiEI (New England
Biolabs) for 1 h at 60°C revealed a G4C2 repeat expansion estimated to consist
of∼50 repeats. Next, the TRE-90CGG-GFP vector (Hukema et al., 2014) was
restricted with SacII (New England Biolabs), and the 90xCGG repeat
expansion was replaced with the 50x G4C2 repeat expansion. This vector was
sequenced using a primer in the TRE sequence (5′-CGGGTCCAGTAGG-
CGTGTAC-3′) and revealed a repeat expansion of 36×G4C2. The final vector
was cut with AatII, PvuI and NdeI (NEB), and the band containing the TRE-
36×G4C2-GFP construct was isolated from a gel, dissolved in injection buffer
(10 mM Tris-HCl, pH 7.4, 0.25 mM EDTA) and used to generate transgenic
mice. Experiments on human material were performed under informed
consent and approved by the Medical Ethical Test Committee (METC). All
investigations with human materials were conducted according to the
principles expressed in the Declaration of Helsinki.
Animals
Pronuclei from oocytes of C57BL/6JRj wild-type mice were injected to
create a new transgenic line harboring the TRE-36×G4C2-GFP construct.
Genotyping was performed using primers located in the 5′ region of the
repeat expansion (forward, 5′-GGTACCCGGGTCGAGGTAGG-3′ and
reverse, 5′-CTACAGGCTGCGGTTGTTTCC-3′). Founder mice, F1 and
F2, were screened in an animal welfare assessment by the local animal
caretakers and scored as normal for litter size and health characteristics. All
mice were housed in groups of two to four and were allowed to have free
access to standard laboratory food and water. They were kept in a 12-h light/
dark cycle. TRE-36×G4C2-GFP mice were crossed with hnRNP-rtTA
(Katsantoni et al., 2007) or Camk2-alpha-rtTA (kind gift of Rob Berman,
The University of California, Davis, USA) on a C57BL/6JRj wild-type
background. Offspring should include 25% of DT mice (harboring both the
TRE and one of the rtTA constructs), 50% of ST littermates (harboring
either the TRE or the rtTA construct) and 25% of wild-type littermates
(having no transgene). At 6 weeks of age, mice of both sexes were exposed
to dox (Sigma-Aldrich) (4 grams/l) combined with sucrose (50 grams/l)
dissolved in drinking water. Both ST and DT mice received dox water. To
monitor their health and wellbeing, mice were weighed every weekday
while on dox water (data not shown). TRE-36×G4C2-GFP/hnRNP-rtTA
mice were sacrificed by cervical dislocation after a maximum of 4 weeks of
dox administration. The TRE-36×G4C2-GFP/Camk2-alpha-rtTA mice were
sacrificed by cervical dislocation after a maximum of 24 weeks of dox
administration. As required by Dutch legislation, all experiments were
approved in advance by the institutional Animal Welfare Committee
(Erasmus University Medical Center, Rotterdam, The Netherlands).
Erasmus ladder
The Erasmus ladder (Noldus, Wageningen, The Netherlands) is a fully
automated test for detecting motor performance in mice (Vinueza Veloz
et al., 2012). It consists of a horizontal ladder between two shelters, which
are equipped with a bright white LED spotlight and pressurized air outlets.
These are used as cues for the departure from the shelter box to the other
shelter box. The ladder has 2×37 rungs for the left and right side. All rungs
have pressure sensors, which are continuously monitoring and registering
the walking pattern of the mouse. The rungs are placed in an alternating
high/low pattern.Wild-type C57Bl6mice prefer towalk on the higher rungs,
avoiding touching the lower rungs (Vinueza Veloz et al., 2015). The mouse
was placed in the starting box and after a period varying from 9 to 11 s,
the LED light turned on and the mouse was supposed to leave the box. If the
mouse left the box before the light turned on a strong air flow drove the
mouse back into the box, and the waiting period restarted. If the mouse did
not leave the box within 3 s after the light turned on, a strong air flow drove
the mouse out of the box. When the mouse arrived in the other box, the
lights and air flow turned off and the waiting period from 9 to 11 s started
and the cycle repeated again, making mice run back and forth on the ladder.
Mice were trained on the Erasmus ladder at the age of 5 weeks, every day for
5 days. The mice were trained to walk the ladder for 42 runs each day. At the
age of 6 weeks, the mice received dox/sucrose water and were tested on
Monday, Wednesday and Friday on the Erasmus ladder. The average
percentage of lower rung touches was calculated over 42 runs per session.
NMJ staining
EDL muscles were fixed in 1% paraformaldehyde overnight. The muscles
were washed in PBS and permeabilized in 2.5% Triton X-100 (Sigma-
Aldrich) in PBS for 30 min and incubated in 1 µg/ml α-bungarotoxin-
TRITC (Invitrogen) in 1 M NaCl for 30 min. Subsequently, muscles were
incubated for 1 h in a blocking solution [4% bovine serum albumin (BSA),
0.5% Triton X-100]. After blocking, the muscles were incubated with a
polyclonal chicken anti-neurofilament antibody (2BScientific) 1:500 in
blocking solution overnight at 4°C, followed by incubation for 4 h with anti-
chicken Alexa Fluor 488 antibody (Jackson ImmunoResearch). Finally, the
muscles were mounted on slides with 1.8% low-melting point agarose
(Thermo Fisher Scientific) and images were taken using a Zeiss LSM700
confocal microscope. The first author was blinded during image acquisition.
Fluorescent in situ hybridization
Brain and EDL muscle tissues of mice were fixed in 4% paraformaldehyde
overnight. Tissues were dehydrated and embedded in paraffin, and cut into
6 µm sections using a rotary microtome. Post-mortem human C9FTD/ALS
frontal cortex paraffin tissue was used as a positive control for RNA foci
detection. Sections were deparaffinized using xylene, and rehydrated in a
standard alcohol series. Antigen retrieval was established in 0.01 M sodium
citrate with pH 6 using microwave treatment of 1×9 min followed by
2×3 min at 800W. Subsequently, the slides were dehydrated in an alcohol
series and briefly dried in air. Next, pre-hybridization was performed in
hybridization solution (dextran sulphate 10% w/v, formamide 50%, 2×
SSC) for 1 h at 65°C. After pre-hybridization, hexanucleotide sense oligo
(5′-Cy5-4xGGGGCC-3′) and hexanucleotide antisense oligo (5′-Cy5-
4xCCCCGG-3′) probes (IDT) were diluted to 40 nM in hybridization
solution and heated to 95°C for 5 min. The slides were hybridized with
probe mix overnight at 65°C. After hybridization, the slides were washed
once with 2× SSC/0.1% Tween 20 and three times with 0.1× SSC at 65°C.
Subsequently, slides were stained with Hoechst (Invitrogen), washed with
PBS and stained with Sudan Black (Sigma-Aldrich). Finally, slides were
dehydrated and mounted using Pro-Long Gold mounting solution
(Invitrogen), and images were taken using a Zeiss LSM700 confocal
microscope. C9FTD/ALS and non-demented control human brain sections
were provided by the Dutch Brain Bank.
Immunohistochemistry
Mouse tissues were fixed in 4% paraformaldehyde overnight, and dehydrated
and embedded in paraffin. Sections (6 µm) were cut using a rotary microtome.
Sections were deparaffinized using xylene and rehydrated in an alcohol series.
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Antigen retrieval was established in 0.01 M sodium citrate with pH 6 using
microwave treatment of 1×9 min followed by 2×3 min at 800W. Endogenous
peroxidase activity was blocked with 3% H2O2 and 1.25% sodium azide.
Immunostaining was performed overnight at 4°C in PSB block buffer (1×
PBS/0.5% protifar/0.15% glycine) and with the primary antibodies (see
Table S1 for all antibodies used in this study). The next day, sections were
washed with PBS block buffer, and antigen-antibody complexes were
visualized by incubation with DAB substrate (Dako) after incubation with
Brightvision poly-horseradish peroxidase (HRP)-linker (Immunologic) or
anti-mouse/rabbit HRP (Dako). Slides were counterstained with Mayer’s
haematoxylin and mounted with Entellan (Merck Millipore). The slides were
imaged using an Olympus BX40 microscope.
Protein isolation
Before lysing, EDL muscle samples were thawed on ice and supplied with
RIPA buffer containing 0.05% protease inhibitors (Roche) and 0.3% 1 M
DTT (Invitrogen). Samples were mechanically lysed, followed by 30 min
incubation on ice. After 30 min incubation, mechanical lysing was repeated
and samples were centrifuged for 20 min at 17 g at 4°C, followed by
3×1 min sonication. After sonication, samples were centrifuged for 20 min
at 17 g at 4°C and the supernatant was used for ELISA. Whole protein
content was determined using a BCA assay (Thermo Fisher Scientific).
ELISA
MaxiSorp 96-well F-bottom plates (Thermo Fisher Scientific) were coated
for 2 h with 5 µg/ml monoclonal GR antibody, followed by overnight
blocking with 1% BSA in PBS-Tween (0.05% Tween 20, Sigma-Aldrich) at
4°C. After washing, 300 µg total protein lysate was added per sample. A 15x
GR synthetic peptide (LifeTein) was used as a positive control. This peptide
was serial diluted to create a standard curve (in duplo). All samples were
measured both undiluted and diluted 2× and 4× with 0.1 M PBS. Samples
and GR peptide were incubated on the plate for 1 h at room temperature.
After washing, all wells were incubated for 1 h with biotinylated
monoclonal anti-GR antibody at a final concentration of 0.25 µg/ml in
PBS-Tween 20/1% BSA. After washing again, samples were incubated for
20 min with Streptavidin-HRP (R&DSystems) diluted 1:200 in PBS-Tween
20/1% BSA. Following extensive washing, samples were incubated with
substrate reaction mix (R&D Systems) for 15 min and stopped using 2N
H2SO4. Read-out was carried out using a plate reader (Varioskan) at 450 nm
and 570 nm.
C9ORF72 strand-specific RT-PCR
RNA isolation was performed on mouse frozen kidney tissue and frozen
frontal cortex of two C9FTD patients. Tissue was homogenized in 500 µl
RIPA buffer (150 mM NaCl; 5 mM EDTA; 50 mM Tris-HCl, pH 8.0; 1%
Nonidet-P40; 0.5% sodium deoxycholate; and 0.1% SDS, pH 7.6)
containing complete protease inhibitor (Roche), 3 mM DTT (Invitrogen)
and 40 units of RNAse OUT (Invitrogen). RNA was isolated using TRIzol
reagent (Invitrogen), according to manufacturer’s instructions. Reverse
transcription was performed with 250 ng of RNA using a SuperScriptIII
cDNA Synthesis kit (Invitrogen), according to manufacturer’s instructions.
RNA was treated with DNase before cDNA synthesis. The following
C9ORF72 strand-specific primers were used to generate cDNA: LK-
ASORF-R, 5′-CGACTGGAGCACGAGGACACTGACGAGTGGGTGA-
GTGAGGAG-3′ (after repeat) (Zu et al., 2013); or LK-ASORF-R2, 5′-
CGACTGGAGCACGAGGACACTGAGTAGCAAGCTCTGGAACT-
CAGGAGTCG-3′ (before repeat) (Liu et al. 2017; Rizzu et al. 2016).
For C9 FTD patient samples, PCR was performed using LK specific
primer, 5′-CGACTGGAGCACGAGGACACTGA-3′ and reverse pri-
mer, 5′-AGTCGCTAGAGGCGAAAGC-3′. For mouse samples, PCR
was performed using LK specific primer, 5′-CGACTGGAGCACGA-
GGACACTGA-3′ and reverse primer, 5′-CTCCTCACTCACCCACTCG-3′.
The PCR program was as follows: 4 min at 94°C, followed by 35 cycles of
45 s at 94°C, 45 s at 58°C and 90 s at 72°C, followed by 6 min at 72°C.
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Figure S1: Alignment of DNA sequence of mouse 
transgene (lower case) and human C9ORF72 sequence 
(upper case/ capital letters) surrounding the repeat 
expansion. NCBI Reference Sequence: NG_031977.1. Our 
mouse model contains 118 bp upstream and 115 bp 
downstream human flanking region around the G4C2 repeat 
expansion.
























































































Figure S2: GFP expression in EDL muscle, heart, lung, liver and kidney of TRE-36xG4C2-
GFP/hnRNP-rtTA double transgenic mice. No GFP staining was observed in the hippocampus 
dentate gyrus or in the spinal cord of DT mice. Single transgenic littermates, consist-ing of either 
TRE-only or rtTA-only, received the same dox treatment and are all negative for GFP staining. 
Scale bars are 20 µm. All stainings were performed on all mice in this study. ST 4 weeks dox 
n=15, DT 4 weeks dox n=16
































































Figure S3: No sense nor antisense RNA foci were found in 
TRE-36xG4C2-GFP/Camk2-alpha-rtTA and TRE-36xG4C2-GFP/hnRNP-rtTA double trans-
genic mice and control single transgenic littermates. Single and double transgenic mice 
received the same dox treatment. Only frontal cortex samples of C9FTD cases present with 
some nuclear sense and antisense foci. Scale bars are 10 µm. The FISH was performed on all 
mice in this study. ST 4 weeks dox n=15, DT 4 weeks dox n=16


















































































































rt-PCR for C9orf72 antisense transcipts on 
































































Figure S4: reverse transcriptase PCR for C9orf72 antisense tran-scripts. A) rt-
PCR for C9orf72 antisense transcripts on frozen human prefrontal cortex samples 
with C9orf72 reverse specific primers. PCR product is only expected in C9ALS/
FTD patients and is around 170bp without repeat, longer for the small repeat in 
C9FTD patient 1 and absent due to unknown reasons in C9FTD patient 2. Non-demented 
controls and samples run without reverse transcriptase show no bands (as expected) or 
some a-specific bands. B) rt-PCR for C9orf72 antisense transcripts on TRE- 
36xG4C2-GFP mouse kidney samples with C9orf72 reverse specific primers. PCR product 
is only expected in double transgenic (DT) mouse samples if any antisense transcription 
would be present, the PCR product would be around 360bp including the 36 repeat. Single 
transgenic (ST) and samples without reverse transcriptase (rt) are empty except for primer 
dimers (as expected). Lane number 4 is left empty because of broken well.
























































































Figure S5: Poly-GA expression in EDL muscle, lung, liver and kidney of TRE-36xG4C2-
GFP/hnRNP-rtTA double transgenic mice. No poly-GA staining was observed in the 
hippocampus dentate gyrus or in the spinal cord of DT mice. Single transgenic littermates, 
consisting of either TRE-only or rtTA-only, were treated similarly with dox and are all negative 
for poly-GA staining. Scale bars are 20 µm. The poly-GA was performed on all mice in this 
study. ST 4 weeks dox n=15, DT 4 weeks dox n=16











































































































































Figure S6: Expression of 36x G4C2 human repeats does not cause 
abundant p62, pTDP-43 and cleaved-caspase 3 pathology. Human 
prefrontal cortex of A) C9FTD patients or B) non-demented controls were 
used as positive and negative control for detection of pathology. C) 
TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic mice do not present with 
any p62, pTDP-43 or cleaved-caspase-3 pathology in EDL muscle. E) 
TRE-36xG4C2-GFP/Camk2-alpha-rtTA double transgenic mice show some 
sparse perinuclear aggregates of p62 in the hippocampus dentate gyrus 
(arrow). D) and F) Single transgenic littermates, consisting of either TRE-on-
ly or rtTA-only, were treated similarly with dox and are negative for all 
pathology. All scale bars are 20 µm. All stainings were performed on all mice 
in this study. ST 4 weeks dox n=15, DT 4 weeks dox n=16.


























































































Figure S7: TRE-36xG4C2-GFP/Camk2-alpha-rtTA double transgenic mice do not show 
astrogliosis or microgliosis. A) Astrogliosis was assessed with GFAP labeling and B) 
microgliosis was tested with Iba1 staining. No differences in amount or morphology of 
GFAP-positive and Iba1-positive cells were seen in the hippocampus dentate gyrus of 
TRE-36xG4C2-GFP/Camk2-alpha-rtTA double transgenic mice and single transgen-ic 
control littermates. Single transgenic littermates, consisting of either TRE-only or rtTA-only, 
were treated similarly with dox. Scale bars are 20 µm. C) To quantify the thickness of 
Iba1-positive neurites, averages were taken of 10 pictures per mouse. N=8 
TRE-36xG4C2-GFP/Camk2-alpha-rtTA double transgenic mice and n=8 single transgenic 
controls. T-test p=0.9099.
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8 Steps from higher to lower rungs
hnRNP-rtTA / TRE-36xG4C2-GFP
Figure S8: Erasmus ladder readouts. A) Step times of short steps (from one higher rung to the next; 
left) and long steps (skipping one higher rung, right). B) Fraction of short and long steps of all steps. C) 
Fraction of steps that were made from a higher rung to a lower rung. Lines indicate medians and shaded 
areas the interquartile ranges. 


















































































































































Figure S9: GFP and sense DPRs are cleared from the kidney after 2 weeks of dox 
withdrawal. A) GFP staining on kidney of TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic 
mice shows clearance of GFP staining when mice received 2 weeks of dox water followed by 2 
weeks of normal drinking water compared to DT littermates that received 4 weeks of dox. B) Poly-
GA staining of kidney shows clearance of poly-GA after two weeks of dox withdrawal. C) Poly-GP 
staining and D) Poly-GR staining are also cleared from kidneys after 2 weeks of dox withdrawal. 
Single transgenic littermates received 2 or 4 weeks of dox and are all negative for GFP and DPRs. 
All scale bars are 50 µm. All stainings were performed on all mice in this study. Num-bers per 
group are: ST 1 week dox n=7, DT 1 week dox n=8, ST 1 week on/3 weeks off n=4, DT 1 week 
on/3 weeks off n=7, ST 2 weeks dox n=6, DT 2 weeks dox n=8, ST 2 weeks on/2 weeks off n=6, 
DT 2 weeks on/2 weeks off n=5, ST 4 weeks dox n=15, DT 4 weeks dox n=16






























Table S1. Antibodies 
Ab name Host Company Cat.nr Dilution 
GA mouse Millipore, clone 5E9 MABN889 1:500 
GP rabbit Bio Connect Life Sciences 24494-1-AP 1:250 
GR mouse LifeTein Services n.a. (costum-made) 1:4000 
PR mouse LifeTein Services n.a. (costum-made) 1:500 
PA mouse Gift from Petrucelli n.a. 1:2500 
pTDP-43 mouse Cosmo bio CAC-TIP-PTD-
M01 
1:1000 
p62 mouse BD Biosciences 610833 1:100 
Neurofilament chicken 2BScientific Ltd. CPCA-NF-H-25ul 1:500 
GFAP Rabbit Sigma G-9269 1:100 
Iba1 rabbit Wako 019-19741 1:200 
ChAT goat Chemicon AB144P 1:500 
poly-HRP anti 
Ms/Rb IgG 
goat Immunologic DPV055HRP undiluted 
anti-mouse 
HRP 
goat DAKO P0260 1:100 
anti-rabbit HRP  goat DAKO P0217 1:100 
anti-mouse Cy2 goat Jackson 715-255-150 1:100 
anti-rabbit Cy3 goat Jackson 711-165-152 1:100 
anti-chicken 
488 
goat Jackson 303-545-006 1:100 
anti-goat HRP rabbit DAKO P0449 1:100 
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